Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVV858 with or without endocrine therapy in HR+/HER2- breast cancer and other advanced solid tumors
jRCT2051250232Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Feb 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of GVV858 in breast cancer, Nonhematologic neoplasms and castration-resistant prostate cancer (CRPC) (5 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of dose-limiting toxicities (DLTs), Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) and 2 more. Started Feb 2026; status: recruiting.
02
Drugs
GVV858
03
Conditions
breast cancerNonhematologic neoplasmscastration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on jRCT2051250232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250232.